T. Rowe Price Associates’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

T. Rowe Price Associates’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-9,640	Closed	-$463K	–	2585
2020 Q1	$463K	Buy	+9,640	New	+$448K	﹤0.01%	2023

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

T. Rowe Price Associates's RARX Position: Q2 2020 in Review

T. Rowe Price Associates sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 9,640 shares — an estimated $463K sold.

T. Rowe Price Associates first reported a position in RARX in Q1 2020 and held it in 1 quarter. The position peaked at $463K in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

T. Rowe Price Associates reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
T. Rowe Price Associates sold 9,640 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $463K.
T. Rowe Price Associates first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
T. Rowe Price Associates's Ra Pharmaceuticals, Inc. Common Stock position peaked at $463K in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.